Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study

References

• Park IH, Pritchard DG, Cartee R, et al. Discovery of a new capsular serotype (6C) within serogroup 6 of streptococcus pneumoniae. J Clin Microbiol. 2007;45(4):1225–1233. doi: 10.1128/JCM.02199-06
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• WHO. Pneumonia in children. 2022 Nov11. [cited 2023 Jul 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/pneumonia
   Google Scholar
• Namkoong H, Ishii M, Funatsu Y, et al. Theory and strategy for pneumococcal vaccines in the elderly. Hum Vaccin Immunother. 2016;12(2):336–343. doi: 10.1080/21645515.2015.1075678
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi: 10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Sun JF, Yao HY, Yu SC, et al. Disease burden of three kinds of bacterial meningitis in China,1990 and 2010. Disease Sur. 2015;30(12):1008–1013.
   Google Scholar
• Zhang Y, Shu JD. Pneumococcal pneumonia and its vaccines. Chin J Epidemiol. 2002;23(1):78.
   Google Scholar
• Lyu S, Yao KH, Dong F, et al. Vaccine serotypes of streptococcus pneumoniae with high-level antibiotic resistance isolated more frequently seven years after the licensure of PCV7 in Beijing. Pediatr Infect Dis J. 2016;35(3):316–321. doi: 10.1097/INF.0000000000001000
   PubMed Web of Science ®Google Scholar
• Song JH. Advances in pneumococcal antibiotic resistance. Expert Rev Respir Med. 2013;7(5):491–498. doi: 10.1586/17476348.2013.816572
   PubMed Web of Science ®Google Scholar
• Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56(3):1418–1426. doi: 10.1128/AAC.05658-11
   PubMed Web of Science ®Google Scholar
• Beard JR, Bloom DE. Towards a comprehensive public health response to population ageing. Lancet. 2015;385(9968):658–661. doi: 10.1016/S0140-6736(14)61461-6
   PubMed Web of Science ®Google Scholar
• Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496–1503. doi: 10.1016/j.vaccine.2016.02.023
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the immunization strategic advisory group of experts, November 2007–conclusions and recommendations. Wkly Epidemiol Rec. 2008;83(1):1–15. PMID: 18175408.
   PubMedGoogle Scholar
• El-Beyrouty C, Buckler R, Mitchell M, et al. Pneumococcal vaccination-a literature review and practice guideline update. Pharmacotherapy. 2022;42(9):724–740. doi: 10.1002/phar.2723
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang L, Xie M, et al. Recommendations for influenza and streptococcus pneumoniae vaccination in elderly people in China. Aging med (Milton (NSW)). 2020;3(1):1–11. doi: 10.1002/agm2.12102
   PubMedGoogle Scholar
• Nieminen T, Käyhty H, Virolainen A, et al. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine. 1998;16(2–3):313–319. doi: 10.1016/S0264-410X(97)00162-X
   PubMed Web of Science ®Google Scholar
• Zhang GH, Zheng DQ, Shi NM, et al. Pneumonia vaccination coverage and influencing factors among part of community elderly in Chaoyang District, Beijing city, China. Chin J Biol. 2013;26(1):3.
   Google Scholar
• Guo X, Qiu J, Ren J, et al. Efficacy evaluation after 5 years of inoculation of 23 valent pneumococcal polysaccharide vaccine for the elderly aged 60 years old and above in Shanghai during 2013–2018. Chi J Prev Med. 2020;54(9):923–928. doi: 10.3389/fpubh.2021.647725
   Google Scholar
• Guo X, Qiu J, Ren J, et al. Safety evaluation of mass inoculation of 23 valent pneumococcal polysaccharide vaccine among elderly people aged 60 and above in Shanghai from 2013 to 2017. Chi J Prev Med. 2020;54(9):929–933. doi: 10.3760/cma.j.cn112150-20191011-00779
   Google Scholar
• Bacterial Respiratory Pathogen Reference Laboratory. Training manual for enzyme linked immunosorbent assay for the quantitation of streptococcus pneumonia serotype specific IgG (pn PS ELISA). [cited 2023 Jul 7]. (007sp Version). Available from: https://www.vaccine.uab.edu/uploads/mdocs/ELISAProtocol(007sp).pdf
   Google Scholar
• Brian W, O’Brien KL, Adena G, et al. Burden of streptococcus pneumoniae and haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–e757. doi: 10.1016/S2214-109X(18)30247-X
   PubMed Web of Science ®Google Scholar
• Chinese Preventive Medicine Association, vaccine and Immunology Branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version). Chin J Epidemiol. 2020;41(12):35.
   Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PloS one. 2017;12(1):e0169368. doi: 10.1371/journal.pone.0169368
   PubMed Web of Science ®Google Scholar
• Qiu YP, Zhao K, Li X, et al. Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China. Chi J Prev Med. 2016;50(12):1074–1078. doi: 10.3760/cma.j.issn.0253-9624.2016.12.010
   Google Scholar
• Remschmidt C, Harder T, Wichmann O, et al. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. BMC Infect Dis. 2016;16(1):711. doi: 10.1186/s12879-016-2040-y
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR–11):1–18.
   PubMedGoogle Scholar
• Kohlhammer Y, Schnoor M, Schwartz M, et al. Determinants of influenza and pneumococcal vaccination in elderly people: a systematic review. Public Health. 2007;121(10):742–751. doi: 10.1016/j.puhe.2007.02.011
   PubMed Web of Science ®Google Scholar
• Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31(10):1011–1044. doi: 10.1007/s12325-014-0157-1
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–1460. doi: 10.1056/NEJM199111213252101
   PubMed Web of Science ®Google Scholar
• Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J Infect Dis. 2010;201(4):525–533. doi: 10.1086/651131
   PubMed Web of Science ®Google Scholar
• Steens A, Vestrheim DF, Aaberge IS, et al. A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older. Epidemiol Infect. 2014;142(12):2471–2482. doi: 10.1017/S0950268814001514
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kishino H, Kanazu S, et al. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly. Hum Vaccin Immunother. 2018;14(8):1931–1938. doi: 10.1080/21645515.2018.1456611
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46(7):1015–1023. doi: 10.1086/529142
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. an evaluation of current recommendations. JAMA. 1993 Oct 20;270(15):1826–1831. doi: 10.1001/jama.1993.03510150060030
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Ridda I, Trent MJ, et al. Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up. Vaccine. 2019;37(35):5016–5024. doi: 10.1016/j.vaccine.2019.07.005
   PubMed Web of Science ®Google Scholar
• Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516–524. doi: 10.1086/649839
   PubMed Web of Science ®Google Scholar
• Ciprero KL, Marchese RD, Richard P, et al. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. Hum Vaccin Immunother. 2016;12(8):2135–2141. doi: 10.1080/21645515.2016.1156270
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine. 2014;32(21):2399–2405. doi: 10.1016/j.vaccine.2014.02.096
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Romero-Steiner S, Martinez JE, et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis. 2000;181(3):1162–1166. doi: 10.1086/315307
   PubMed Web of Science ®Google Scholar
• Ahn JG, Kim HW, Choi HJ, et al. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. Vaccine. 2015;33(38):4770–4775. doi: 10.1016/j.vaccine.2015.08.002
   PubMed Web of Science ®Google Scholar
• Park S, Nahm MH, Weiser JN. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun. 2011;79(1):314–320. doi: 10.1128/IAI.00768-10
   PubMed Web of Science ®Google Scholar
• Chiarella SE, Jenkins SM, Park MA, et al. Sex differences in antibody responses to the 23-valent pneumococcal polysaccharide vaccination. Ann Allergy Asthma Immunol. 2021;127(4):509–510. doi: 10.1016/j.anai.2021.07.013
   PubMed Web of Science ®Google Scholar
• Parker AR, Skold M, Harding S, et al. Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations. BMC Immunol. 2019;20(1):29. doi: 10.1186/s12865-019-0310-3
   PubMed Web of Science ®Google Scholar
• Goldblatt D, McKeen A, Burbidge P, et al. Assignment of weight-based antibody units for four additional serotypes to a human antipneumococcal standard reference serum, 007sp. Clin Vaccine Immunol. 2017 Sep 5;24(9):e00194–17. doi: 10.1128/CVI.00194-17
   PubMedGoogle Scholar
• LaFon DC, Nahm MH. Measuring immune responses to pneumococcal vaccines. J Immunol Methods. 2018;461:37–43. doi: 10.1016/j.jim.2018.08.002
   PubMed Web of Science ®Google Scholar